Zentalis Pharmaceuticals, Inc. (ZNTL)
3.11
+0.03
(+0.97%)
USD |
NASDAQ |
Sep 18, 16:00
3.11
0.00 (0.00%)
After-Hours: 20:00
Zentalis Pharmaceuticals Enterprise Value : 85.97M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 85.97M |
| September 17, 2026 | 83.82M |
| September 16, 2026 | 85.25M |
| September 15, 2026 | 87.40M |
| September 14, 2026 | 113.92M |
| September 11, 2026 | 114.64M |
| September 10, 2026 | 120.37M |
| September 09, 2026 | 135.42M |
| September 08, 2026 | 151.91M |
| September 04, 2026 | 149.04M |
| September 03, 2026 | 157.64M |
| September 02, 2026 | 133.27M |
| September 01, 2026 | 128.97M |
| August 31, 2026 | 132.56M |
| August 28, 2026 | 135.42M |
| August 27, 2026 | 141.16M |
| August 26, 2026 | 141.87M |
| August 25, 2026 | 141.16M |
| August 24, 2026 | 132.56M |
| August 21, 2026 | 137.21M |
| August 20, 2026 | 138.29M |
| August 19, 2026 | 136.86M |
| August 18, 2026 | 126.82M |
| August 17, 2026 | 128.61M |
| August 14, 2026 | 118.22M |
| Date | Value |
|---|---|
| August 13, 2026 | 160.51M |
| August 12, 2026 | 170.54M |
| August 11, 2026 | 157.64M |
| August 10, 2026 | 160.51M |
| August 07, 2026 | 165.52M |
| August 06, 2026 | 221.42M |
| August 05, 2026 | 217.84M |
| August 04, 2026 | 212.82M |
| August 03, 2026 | 196.34M |
| July 31, 2026 | 202.79M |
| July 30, 2026 | 215.69M |
| July 29, 2026 | 197.77M |
| July 28, 2026 | 194.19M |
| July 27, 2026 | 186.31M |
| July 24, 2026 | 173.41M |
| July 23, 2026 | 182.01M |
| July 22, 2026 | 185.59M |
| July 21, 2026 | 222.14M |
| July 20, 2026 | 222.14M |
| July 17, 2026 | 229.31M |
| July 16, 2026 | 190.61M |
| July 15, 2026 | 205.66M |
| July 14, 2026 | 204.94M |
| July 13, 2026 | 194.19M |
| July 10, 2026 | 212.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ARS Pharmaceuticals, Inc. | 361.52M |
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.29M |
| Total Expenses (Quarterly) | 42.29M |
| EPS Diluted (Quarterly) | -0.5929 |
| Earnings Yield | -62.94% |
| Normalized Earnings Yield | -63.32 |